Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants
With the advancement of effective antiretroviral therapy, people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the...
Gespeichert in:
| Veröffentlicht in: | AIDS research and human retroviruses 2023-12, Vol.39 (12), p.662-670 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 670 |
|---|---|
| container_issue | 12 |
| container_start_page | 662 |
| container_title | AIDS research and human retroviruses |
| container_volume | 39 |
| creator | Ramirez, Hasmin C Monroe, Anne K Byrne, Morgan O'Connor, Lauren F |
| description | With the advancement of effective antiretroviral therapy, people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the association between comorbidity burden, measured using a modified Quan-Charlson Comorbidity Index (QCCI), and VS (viral load result of |
| doi_str_mv | 10.1089/aid.2022.0186 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10712358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2832576331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-e94e76f1064f5b9cf4aa4c1111f4a683cf6e5c2d226631a948f7f2d2929022733</originalsourceid><addsrcrecordid>eNqFkUtv1DAURi0EokNhyRZ5ySaDH3nYbNAQCh2pCFChW8vj3HSMEju1Hej8F34sjqZUsMILP4-Pr_wh9JySNSVCvtK2WzPC2JpQUT9AKyo5LURJqodoRYSQBWNMnqAnMX4nhEjGqsfohDdcLpdW6NfZrR6ts-4apz3gTYzeWJ2sd_gtpJ8ADmv80Xe2t9DhL7N2RbvXYYgZaP3ow852Nh3w1nVwi7Xr8Pn2Cl_ZoAd8OU9TgBiz7DXe4Db4GItLMIs9H29yd4g2Yt_jd2227X1I-LMOyRo7aZfiU_So10OEZ3fjKfr2_uxre15cfPqwbTcXheFCpAJkCU3dU1KXfbWTpi-1Lg3NLc9qwU1fQ2VYx1hdc6plKfqmz0vJZP6DhvNT9ObonebdCJ0Bl3L9agp21OGgvLbq3xNn9-ra_1CUNJTxSmTDyztD8DczxKRGGw0Mg3bg56iY4Kxqas5pRosjapb_CNDfv0OJWiJVOVK1pKOWSDP_4u_i7uk_GWaAH4FlWzs3WNhBSP_R_gZqkrAU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2832576331</pqid></control><display><type>article</type><title>Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ramirez, Hasmin C ; Monroe, Anne K ; Byrne, Morgan ; O'Connor, Lauren F</creator><creatorcontrib>Ramirez, Hasmin C ; Monroe, Anne K ; Byrne, Morgan ; O'Connor, Lauren F ; DC Cohort Executive Committee</creatorcontrib><description>With the advancement of effective antiretroviral therapy, people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the association between comorbidity burden, measured using a modified Quan-Charlson Comorbidity Index (QCCI), and VS (viral load result of <200 copies/mL). We hypothesized that an increase in QCCI score, indicating a higher risk for mortality, would correlate with lower likelihood of VS because of the burden of comorbidity treatment, possibly leading to worse antiretroviral adherence. Our analysis included participants from the DC Cohort Longitudinal HIV Study in Washington, DC. Eligible participants were aged ≥18 years and enrolled in the cohort as of January 1, 2018 (
n
= 2,471). A modified QCCI score, which weighs selected comorbidities (not including HIV/AIDS) and predicts mortality, was calculated using International Classification of Disease-9/10 codes from electronic health records. Multivariable logistic regressions were used to characterize the association between QCCI composite scores and VS. Participants were predominantly virally suppressed (89.6%), male (73.9%), non-Hispanic Black (74.7%), and between 18 and 55 years (59.3%). The median QCCI score was 1 (range = 1–12, interquartile range = 0–2), demonstrating predominately low mortality risk. We did not establish a statistically significant association between QCCI score and VS (adjusted odds ratio = 1.06, 95% confidence interval 0.96–1.17). Our findings suggest that a higher QCCI score was not associated with lower VS in this population, which may be partly due to the high retention in care among cohort participants.</description><identifier>ISSN: 0889-2229</identifier><identifier>ISSN: 1931-8405</identifier><identifier>EISSN: 1931-8405</identifier><identifier>DOI: 10.1089/aid.2022.0186</identifier><identifier>PMID: 37392022</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc., publishers</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; Adolescent ; Adult ; Anti-Retroviral Agents - therapeutic use ; Comorbidity ; Cross-Sectional Studies ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; Humans ; Male ; Outcomes Research ; Viral Load</subject><ispartof>AIDS research and human retroviruses, 2023-12, Vol.39 (12), p.662-670</ispartof><rights>2023, Mary Ann Liebert, Inc., publishers</rights><rights>Copyright 2023, Mary Ann Liebert, Inc., publishers 2023 Mary Ann Liebert, Inc., publishers</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c388t-e94e76f1064f5b9cf4aa4c1111f4a683cf6e5c2d226631a948f7f2d2929022733</cites><orcidid>0000-0002-7710-7880 ; 0000-0003-3201-3845</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37392022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramirez, Hasmin C</creatorcontrib><creatorcontrib>Monroe, Anne K</creatorcontrib><creatorcontrib>Byrne, Morgan</creatorcontrib><creatorcontrib>O'Connor, Lauren F</creatorcontrib><creatorcontrib>DC Cohort Executive Committee</creatorcontrib><title>Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants</title><title>AIDS research and human retroviruses</title><addtitle>AIDS Res Hum Retroviruses</addtitle><description>With the advancement of effective antiretroviral therapy, people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the association between comorbidity burden, measured using a modified Quan-Charlson Comorbidity Index (QCCI), and VS (viral load result of <200 copies/mL). We hypothesized that an increase in QCCI score, indicating a higher risk for mortality, would correlate with lower likelihood of VS because of the burden of comorbidity treatment, possibly leading to worse antiretroviral adherence. Our analysis included participants from the DC Cohort Longitudinal HIV Study in Washington, DC. Eligible participants were aged ≥18 years and enrolled in the cohort as of January 1, 2018 (
n
= 2,471). A modified QCCI score, which weighs selected comorbidities (not including HIV/AIDS) and predicts mortality, was calculated using International Classification of Disease-9/10 codes from electronic health records. Multivariable logistic regressions were used to characterize the association between QCCI composite scores and VS. Participants were predominantly virally suppressed (89.6%), male (73.9%), non-Hispanic Black (74.7%), and between 18 and 55 years (59.3%). The median QCCI score was 1 (range = 1–12, interquartile range = 0–2), demonstrating predominately low mortality risk. We did not establish a statistically significant association between QCCI score and VS (adjusted odds ratio = 1.06, 95% confidence interval 0.96–1.17). Our findings suggest that a higher QCCI score was not associated with lower VS in this population, which may be partly due to the high retention in care among cohort participants.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Comorbidity</subject><subject>Cross-Sectional Studies</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>Humans</subject><subject>Male</subject><subject>Outcomes Research</subject><subject>Viral Load</subject><issn>0889-2229</issn><issn>1931-8405</issn><issn>1931-8405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAURi0EokNhyRZ5ySaDH3nYbNAQCh2pCFChW8vj3HSMEju1Hej8F34sjqZUsMILP4-Pr_wh9JySNSVCvtK2WzPC2JpQUT9AKyo5LURJqodoRYSQBWNMnqAnMX4nhEjGqsfohDdcLpdW6NfZrR6ts-4apz3gTYzeWJ2sd_gtpJ8ADmv80Xe2t9DhL7N2RbvXYYgZaP3ow852Nh3w1nVwi7Xr8Pn2Cl_ZoAd8OU9TgBiz7DXe4Db4GItLMIs9H29yd4g2Yt_jd2227X1I-LMOyRo7aZfiU_So10OEZ3fjKfr2_uxre15cfPqwbTcXheFCpAJkCU3dU1KXfbWTpi-1Lg3NLc9qwU1fQ2VYx1hdc6plKfqmz0vJZP6DhvNT9ObonebdCJ0Bl3L9agp21OGgvLbq3xNn9-ra_1CUNJTxSmTDyztD8DczxKRGGw0Mg3bg56iY4Kxqas5pRosjapb_CNDfv0OJWiJVOVK1pKOWSDP_4u_i7uk_GWaAH4FlWzs3WNhBSP_R_gZqkrAU</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Ramirez, Hasmin C</creator><creator>Monroe, Anne K</creator><creator>Byrne, Morgan</creator><creator>O'Connor, Lauren F</creator><general>Mary Ann Liebert, Inc., publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7710-7880</orcidid><orcidid>https://orcid.org/0000-0003-3201-3845</orcidid></search><sort><creationdate>20231201</creationdate><title>Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants</title><author>Ramirez, Hasmin C ; Monroe, Anne K ; Byrne, Morgan ; O'Connor, Lauren F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-e94e76f1064f5b9cf4aa4c1111f4a683cf6e5c2d226631a948f7f2d2929022733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Comorbidity</topic><topic>Cross-Sectional Studies</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>Humans</topic><topic>Male</topic><topic>Outcomes Research</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramirez, Hasmin C</creatorcontrib><creatorcontrib>Monroe, Anne K</creatorcontrib><creatorcontrib>Byrne, Morgan</creatorcontrib><creatorcontrib>O'Connor, Lauren F</creatorcontrib><creatorcontrib>DC Cohort Executive Committee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AIDS research and human retroviruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramirez, Hasmin C</au><au>Monroe, Anne K</au><au>Byrne, Morgan</au><au>O'Connor, Lauren F</au><aucorp>DC Cohort Executive Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants</atitle><jtitle>AIDS research and human retroviruses</jtitle><addtitle>AIDS Res Hum Retroviruses</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>39</volume><issue>12</issue><spage>662</spage><epage>670</epage><pages>662-670</pages><issn>0889-2229</issn><issn>1931-8405</issn><eissn>1931-8405</eissn><abstract>With the advancement of effective antiretroviral therapy, people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the association between comorbidity burden, measured using a modified Quan-Charlson Comorbidity Index (QCCI), and VS (viral load result of <200 copies/mL). We hypothesized that an increase in QCCI score, indicating a higher risk for mortality, would correlate with lower likelihood of VS because of the burden of comorbidity treatment, possibly leading to worse antiretroviral adherence. Our analysis included participants from the DC Cohort Longitudinal HIV Study in Washington, DC. Eligible participants were aged ≥18 years and enrolled in the cohort as of January 1, 2018 (
n
= 2,471). A modified QCCI score, which weighs selected comorbidities (not including HIV/AIDS) and predicts mortality, was calculated using International Classification of Disease-9/10 codes from electronic health records. Multivariable logistic regressions were used to characterize the association between QCCI composite scores and VS. Participants were predominantly virally suppressed (89.6%), male (73.9%), non-Hispanic Black (74.7%), and between 18 and 55 years (59.3%). The median QCCI score was 1 (range = 1–12, interquartile range = 0–2), demonstrating predominately low mortality risk. We did not establish a statistically significant association between QCCI score and VS (adjusted odds ratio = 1.06, 95% confidence interval 0.96–1.17). Our findings suggest that a higher QCCI score was not associated with lower VS in this population, which may be partly due to the high retention in care among cohort participants.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc., publishers</pub><pmid>37392022</pmid><doi>10.1089/aid.2022.0186</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7710-7880</orcidid><orcidid>https://orcid.org/0000-0003-3201-3845</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0889-2229 |
| ispartof | AIDS research and human retroviruses, 2023-12, Vol.39 (12), p.662-670 |
| issn | 0889-2229 1931-8405 1931-8405 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10712358 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Acquired Immunodeficiency Syndrome - drug therapy Adolescent Adult Anti-Retroviral Agents - therapeutic use Comorbidity Cross-Sectional Studies HIV Infections - drug therapy HIV Infections - epidemiology Humans Male Outcomes Research Viral Load |
| title | Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A34%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Examining%20the%20Association%20Between%20a%20Modified%20Quan-Charlson%20Comorbidity%20Index%20and%20HIV%20Viral%20Suppression:%20A%20Cross-Sectional%20Analysis%20of%20DC%20Cohort%20Participants&rft.jtitle=AIDS%20research%20and%20human%20retroviruses&rft.au=Ramirez,%20Hasmin%20C&rft.aucorp=DC%20Cohort%20Executive%20Committee&rft.date=2023-12-01&rft.volume=39&rft.issue=12&rft.spage=662&rft.epage=670&rft.pages=662-670&rft.issn=0889-2229&rft.eissn=1931-8405&rft_id=info:doi/10.1089/aid.2022.0186&rft_dat=%3Cproquest_pubme%3E2832576331%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2832576331&rft_id=info:pmid/37392022&rfr_iscdi=true |